Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:02:25.017Z.
Calculation as of: 2026-10-06T18:02:25.017Z.
Quote observation: 2026-10-06T17:58:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 451a64ce4da380df6ab4c5027584c6fd3c25ecc0cb3c19eab7daced69cd0f5b9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$35.69M
PS Ratio
3.03
TTM Avg
7.06
3Y Avg
18.39
5Y Avg
15.88
Market Cap
$33.26M
PS Ratio
1.06
TTM Avg
22.78
3Y Avg
25.26
5Y Avg
324.62
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $34.42M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.06M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $34.48M | 2.84 | 2.34 | 2.93 | 2.48 |
| Accuray Incorporated (ARAY)vs › | $34.21M | 0.09 | 0.16 | 0.35 | 0.48 |
| EUDA Health Holdings Limited (EUDA)vs › | $35.69M | 3.03 | 7.06 | 18.39 | 15.88 |
| DocGo Inc. (DCGO)vs › | $35.81M | 0.12 | 0.22 | 0.47 | 1.32 |
| HeartBeam, Inc. (BEAT)vs › | $33.59M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.26M | 1.06 | 22.78 | 25.26 | 324.62 |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | 1.29 | 6.96 | 23.74 | 23.74 |
| Scilex Holding Company (SCLX)vs › | $32.82M | 1.04 | 1.75 | 2.45 | 15.95 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
Reported statement amounts were converted from USD to USD using the stored FMP exchange-rate calculation.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q2 FY2026Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q3 FY2026Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-12 |
| Q4 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-18 |
| Q1 FY2027Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
